PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
3.37
Current Ratio 1.25–1.5x Drug Manufacturers - Specialty & Generic median of 2.62. Mohnish Pabrai might suspect the market overlooks this liquidity advantage.
1.80
Quick Ratio near Drug Manufacturers - Specialty & Generic median of 1.96. Charlie Munger could see typical near-cash readiness for the sector.
1.23
Cash Ratio near Drug Manufacturers - Specialty & Generic median of 1.15. Charlie Munger would see it as typical for the sector’s operating style.
-6.54
Negative interest coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize earnings quality and look for debt restructuring catalysts.
-0.00
Negative short-term coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize cash flow quality and look for immediate refinancing solutions.